Newsfeed | Navigating EGFR

Fructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells

Read more about Fructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells

Th17 cells are quite heterogeneous. Treating Th17-related inflammatory disorders requires understanding the functionally diverse subtypes in the context of tissue homeostasis, which is shaped by nutrient availability among other factors. Here, we show that increased consumption of fructose exacerbates colitis...

Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors

Read more about Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors

Chimeric Antigen Receptor (CAR) T cells have induced remarkable clinical responses in patients with hematological cancers. However, CAR T-cell therapies against solid tumors have not elicited similar outcomes since immunosuppressive barriers in the tumor microenvironment attenuate anti-tumor activity. Here, we...

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

Read more about Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

Background Afatinib, an irreversible pan-ERBB family inhibitor, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, b 1 Introduction Afatinib, recognized as the first approved ErbB family blocker, irreversibly inhibits signaling from...

Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3-d]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity

Read more about Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3-d]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity

A series of novel furopyrimidine derivatives were designed and synthesized. Compound 3f emerged as the standout candidate with GI of 119.74%. Compound 3f demonstrated a much higher preference for tar Archiv der PharmazieVolume 358, Issue 11 e70146 FULL PAPER Design,...

Design, synthesis, biological evaluation and in-silico study of thioether-linked 4-hydroxycoumarin-benzothiazole derivatives targeting EGFR for cancer therapy

Read more about Design, synthesis, biological evaluation and in-silico study of thioether-linked 4-hydroxycoumarin-benzothiazole derivatives targeting EGFR for cancer therapy

Abstract Non-small cell lung cancer (NSCLC) remains the most prevalent and fatal subtype of lung cancer, with resistance to current EGFR inhibitors posing a major therapeutic challenge. In this study, a novel series of chromone–benzothiazole hybrids (4a–4d) was designed, synthesized,...

CGEM Advances NDA for Zipalertinib Targeting EGFR Mutations in NSCLC

Read more about CGEM Advances NDA for Zipalertinib Targeting EGFR Mutations in NSCLC

An Integrated Clinical‐Radiomics‐Deep Learning Model Based on 18F‐FDG PET/CT for Predicting EGFR Mutation Status in Lung Adenocarcinoma

Read more about An Integrated Clinical‐Radiomics‐Deep Learning Model Based on 18F‐FDG PET/CT for Predicting EGFR Mutation Status in Lung Adenocarcinoma

Background An integrated model combining clinical variables, radiomic features, and deep learning was developed to predict EGFR mutation status in patients with lung adenocarcinoma based on pretreat 1 Introduction Lung cancer is the second most frequently diagnosed cancer worldwide, with...

Suppression of NK cell-mediated immunosurveillance by IL-35 drives tumor progression in EGFR-mutant non-small cell lung cancer

Read more about Suppression of NK cell-mediated immunosurveillance by IL-35 drives tumor progression in EGFR-mutant non-small cell lung cancer

BackgroundInterleukin-35 (IL-35) is an added member of the IL-12 heterodimeric cytokine family, composed of two subunits: EBI3 and P35 subunits, implicated i 1 Introduction Lung carcinoma is responsible for the majority of cancer-related deaths on a global scale, and its...

Subscribe to Newsfeed